
19TH INTERNATIONAL CONFERENCE
SCWD 2026
Scientific programme
Cachexia, Sarcopenia
& Wasting Disorders
From emerging therapies to AI-assisted assessment. Join the scientific conversation shaping the next chapter of muscle health.
Scientific programme
Three days of basic science, translational research and clinical discussion. Browse the sessions, chairs and presentation topics below.
Programme updated 19 November 2026. Speakers, timings and session details remain subject to confirmation.
Programme subject to change.
DEC10DAY 1
Thursday, 10 December 2026
Epigenetics of sarcopenia and cachexia
Chairs
Brittany Counts, USA; Russell Hepple, USA
- Abnormal DNA methylation and altered transcriptome in muscle five years after critical illnessIlse Vanhorebeek, Belgium
- Skeletal muscle methylome-transcriptome disruptions during the onset and progression of colorectal cancer-induced cachexiaNicholas Greene, USA
- BET inhibitors for sarcopeniaGiuseppina Caretti, Italy
- Presentation title to be announcedSpeaker to be announced
- Discussion
Kidney, kidney cancer, and cachexia
Chairs
Srinivasan Dasarathy, USA; Angela Wang, Singapore
- Cachexia as multi-organ diseaseMarilia Seelaender, Brazil
- Tracing Early Oncogenic Events in Renal Cancer: Implications for Cachexia and HIF SignalingJoanna Lima, Brazil
- HIF-2α–driven paraneoplastic syndromes in aggressive kidney cancer: linking PTHrP, hypercalcemia, and cachexiaJames Brugarolas, USA
- The inflammasome connection: NLRP3 at the Crossroads of Cancer and CKD CachexiaRobert Mak, USA
- Discussion
Loss of protein quality control in muscle aging and disease
Chairs
Denis Guttridge, USA; Ilse Vanhorebeek, Belgium
- Protein degradation in disease – insights from human biopsiesVolker Adams, Germany
- Protein aggregation in muscle disease and agingBenjamin Miller, USA
- Integrated stress response in protein quality control in muscleTracy Anthony, USA
- Insolubilome in muscle agingFabio Demontis, USA
- Discussion
Neuromuscular impairments in cachexia and sarcopenia
Chairs
Andrea Bonetto, USA; Richard Lieber, USA
- Impaired motor unit connectivity in cancerJoshua Huot, USA
- New insights on neuromuscular junction instability with inactivityMarco Narici, Italy
- Human neuromuscular organoids mimic cancer-induced muscle wastingPietro Chiolerio, Italy
- A microphysiological model of muscle denervation in pancreatic cancer cachexiaBumsoo Han, USA
- Discussion
Connecting geroscience and osteosarcopenia
Chairs
Marco Brotto, USA; Fabrizio Pin, USA
- The role of the ribosomes in muscle and bone healthSpeaker to be announced
- Targeting optimal recovery in fragility fracture patients with co-existing osteosarcopeniaRonald Man Yeung Wong, Hong Kong
- Tryptophan metabolites as regulators of bone and muscle healthGustavo Duque, Canada
- Cytoskeletal integrators of inflammaging drive osteosarcopeniaChris Ward, USA
- Discussion
Systems biology of cachexia
Chairs
Mauricio Berriel Diaz, Germany; Erin Talbert, USA
- Cross-study meta-analysis of the cancer cachexia transcriptomeYoshiaki Tanaka, Canada
- Functional interrogation of the pancreatic cancer cachexia secretomeDr. Min Deng, NorwayResearcher, Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital
- Cachexia multi-ome analysis reveals early perturbations in adipose tissueHonglei Ji, Germany
- The gut microbiome and cancer cachexiaLaure Bindels, Belgium
- Discussion
Lunch Time Symposium - Supported by Pfizer Inc
Opening session
Chairs
Teresa Zimmers, USA; Stefan Anker, Germany
- WelcomeStefan Anker, Germany
- “Prometheus” basic science keynote lecture · Cachexia and the immune tumor macroenvironmentDenis Guttridge, USA
- “Hippocrates” clinical science keynote lecture · Cancer and cachexia: an oncologist’s perspectiveJeffrey Crawford, USA
- JCSM UpdateStefan Anker, Germany
Multi-organ wasting during incretin treatment
Chairs
Andrew Coats, Australia; Javed Butler, USA
Panelists
David Glass, USA; Stefan Anker, Germany
- Skeletal muscle loss during GLP-1RA based therapies: size of the problem?Jennifer Linge, Sweden
- How does weight cycling affect different tissue compartments?Joseph Brozinick, USA
- Do incretin mimetics cause cardiac atrophy?Markus Anker, Germany
- Can high protein diet prevent muscle wasting?Maurizio Muscaritoli, Italy
- Effect of GLP-1RA and amylin-based assets on body composition and physical function and related outcomesKristoffer Jensen Kolnes, Denmark
- Muscle anabolics during and after GLP-1RA therapy: trial resultsJulio Rosenstock, USA
- Discussion
Mitochondrial dysfunction as a therapeutic target in cachexia: exploring disease-specific mechanisms and shared pathways
Chairs
Volker Adams, Germany; Scott Bowen, UK
- Tumor-driven mitochondrial dysfunction in cancer cachexiaPaola Costelli, Italy
- Mitochondrial dysfunction in age associated cachexiaRussell Hepple, USA
- Mitochondrial function as therapeutic target in cachexiaBeatrice Vahle, Germany
- Novel pharmacological approaches to target mitochondriaTienush Rassaf, Germany
- Discussion
Break
Poster viewing 1
Each presentation: 2 minutes + 2 minutes discussion
- Poster session 1.1 · Cachexia – animal models II (posters 2-12 to 2-23)Chairs: Marilia Seelaender, Jochen Springer
- Poster session 1.2 · Cancer cachexia I (posters 3-01 to 3-11)Chairs: Mauricio Berriel Diaz, Nicholas Greene
- Poster session 1.3 · Muscle Wasting & Sarcopenia I (posters 4-01 to 4-12)Chairs: Joe Chakkalakal, Nicole Welch
- Poster session 1.4 · Muscle Wasting & Sarcopenia III (posters 4-25 to 4-36)Chairs: To be announced
Rapid fire abstracts Session 1
Chairs
Marcus Goncalves, USA; Agata Mossakowski, Germany; Annemie Schols, Netherlands
Each presentation: 3 minutes + 2 minutes discussion
- 15:35–15:40 · Exercise effects on lean mass and strength when added to GLP-1RA therapy for obesity treatment: the M3 study (6-04)Renee J. Rogers, USA
- 15:40–15:45 · From patient voice to clinical endpoints: Developing and validating a fit-for-purpose clinical outcome assessment battery for sarcopenia (6-05)David Cella, USA
- 15:45–15:50 · Impact of intravenous iron supplementation on physical performance in patients with ME/CFS and iron deficiency: the IRON-ME study (7-05)Nadja Jauert, Germany
- 15:50–15:55 · Regenerating skeletal muscle after cancer therapy-induced tissue wasting (7-07)Michael Hicks, USA
- 15:55–16:00 · Protective effect of Zn-specific chelator N,N,N′,N′-Tetrakis-(2-pyridylmethyl) ethylenediamine on chronic kidney disease-induced myopathy (7-08)Jia-Hua Jhuang, Taiwan
- 16:00–16:05 · Divergent systemic and intratumoral immunometabolic effects of Interleukin-4 associated with the prevention of cancer cachexia (7-09)Giacomo Rubini, Italy
- 16:05–16:10 · Development and characterization of preclinical rodent models of skeletal muscle atrophy (7-10)Kylie Heitman, USA
- 16:10–16:15 · Melanocortin agonism drives lean-mass-sparing weight loss with increased energy expenditure in animal models of obesity (7-12)Allison Gardner, USA
Biology, bulk, and function. What is the intersection in cancer cachexia?
Chairs
Jose Garcia, USA; Joshua Huot, USA
- How neural and physiologic mechanisms integrate to dictate muscle function: translational examplesRichard L. Lieber, USA
- Distinguishing functional decline and recovery: preclinical and clinical lessons in cachexiaIshan Roy, USA
- Muscle mass is not enough: distinct roles for muscle quality and mass in functionWilliam Evans, USA
- Muscle remodeling in cachexia: mechanisms linking cellular biology to contractile functionBrittany Counts, USA
- Discussion
Muscle disorders in acute medical care
Chairs
Wolfram Doehner, Germany; Reshma Merchant, Singapore
- Muscular disease in the acute medical care setting – update 2026Joerg C. Schefold, Switzerland
- Skeletal muscle dysfunction during exercise in Long COVIDDavid Systrom, USA
- Neuromuscular dysfunction in critical illness: Progress in understanding and implications for recoveryStephanie Hiser, USA
- Suggested clinical approaches to acute muscle wasting in the critically illStefan Schaller, Austria
- Discussion
Targeting the biology of cachexia in cancer: from disease burden to clinical impact
Chairs
Stefan Anker, Germany; Jeffrey Crawford, USA
- Cancer cachexia in non-small cell lung cancer: epidemiology, prevalence and clinical consequencesMarkus Anker, Germany
- A novel multimodal therapeutic approachAndrew Coats, Australia
- Evaluating S-pindolol in patients with NSCLC and cancer cachexiaUwe Pelzer, Germany
- Panel discussion
SCWD symposium supported by Actimed Therapeutics
Welcome reception · Joint poster viewing
Join the opening conversations.
SCWD 2026 · Washington, DC · December 10–12
DEC11DAY 2
Friday, 11 December 2026
Cachexia in critical illness
Chairs
Stefan Schaller, Austria; Angela Wang, Singapore
- Cachexia in CKD and AKIKamyar Kalantar-Zadeh, USA
- StrokeWolfram Doehner, Germany
- Cachexia in sepsisOrlando Laitano, USA
- Cachexia induced by liver growth and injuryLeonidas Koniaris, USA
- The effect of sleep abnormalities on body compositionMarcello Maggio, Italy
- Discussion
COACH-ED: crosstalks on diagnosing and treating cancer cachexia
Chairs
Maurizio Muscaritoli, Italy; Richard Skipworth, UK
- Diagnosing and managing cachexia in the oncology and palliative care settingEgidio Del Fabbro, USA
- Beyond calories: nutrients as active therapeutics in oncology carePaula Ravasco, Portugal
- Clinical trials and innovation in cancer cachexia careUwe Pelzer, Germany
- COACH-ED: program outcomes and future directions – the road aheadJose Garcia, USA
- Discussion
Break
Poster viewing 2
Each presentation: 2 minutes + 2 minutes discussion
- Poster session 2.1 · Cachexia (posters 1-01 to 1-10)Chairs: Giuseppina Caretti, Neil Greening
- Poster session 2.2 · Therapeutic Development (clinical & pre-clinical) (posters 7-01 to 7-14)Chairs: David Glass, Henning Langer
- Poster session 2.3 · Cancer cachexia II (posters 3-12 to 3-22)Chairs: Tracy Anthony, Ed Reznik
- Poster session 2.4 · Cachexia – animal models III (posters 2-24 to 2-36)Chairs: Tobias Janowitz, Jochen Springer
Rapid fire abstracts Session 2
Chairs
Faisal Beg, Canada; Grace Kulik, USA
Each presentation: 3 minutes + 2 minutes discussion
- 09:35–09:40 · High-throughput 3D light-sheet imaging of mouse hindlimbs enables skeletal muscle morphometrics in muscle wasting models (4-04)Matteo Oliverio, Denmark
- 09:40–09:45 · MitoXcel™ geropeptide PTC-2105 attenuates terminal lean-mass decline in aged mice and semaglutide-associated lean-mass loss (4-09)Kevin Slawin, USA
- 09:45–09:50 · Identifying a protective role for UBR-box E3 ubiquitin ligases in age-related skeletal muscle wasting through the NRF2/Hmox1 pathway (4-14)Emma J. Sanderson, USA
- 09:50–09:55 · Single-nucleus multi-omics reveals reversible molecular signatures in exercise-intolerant skeletal muscle of patients with heart failure with preserved ejection fraction (4-19)Maya Bose, USA
- 09:55–10:00 · Discordance between formula-estimated and DXA-derived body composition highlights the prognostic role of fat mass in men with chronic heart failure (4-25)Ryosuke Sato, Germany
- 10:00–10:05 · Conversion to high urinary titin marks concurrent loss of muscle strength, but not muscle mass, in type 2 diabetes: a 3-year prospective cohort study (4-38)Michio Shimabukuro, Japan
- 10:05–10:10 · Blood-based biomarkers of biological aging and risk of incident sarcopenia in community-dwelling older adults: findings from the Health ABC study (4-43)Danae C. Gross, USA
- 10:10–10:15 · Mitochondrial respiratory capacity of Skeletal muscle is reduced in patients with ME/CFS: high-resolution respirometry analysis from the VADYS-ME study (4-48)Tilman Kalk, Germany
SCWD scientific session sponsored by Nestlé
Chairs
To be announced
- Presentations to be announced.
Biomarkers and mechanisms in cancer cachexia
Chairs
Erin Talbert, USA; Eileen White, USA
- JAK1/2 inhibition delays cachexia and improves survival through increased food intakeMarcus Goncalves, USA
- Responder analysis in the PACTO trialTeresa Zimmers, USA
- Unmasking complement: a causal pathway in cancer-induced muscle lossAndrew Judge, USA
- Plasma Hsp90 Level correlates with cachexia and shorter survival in cancer patientsYi-Ping Li, USA
- Discussion
Cancer cachexia emerging therapies
Chairs
Jeffrey Crawford, USA; Uwe Pelzer, Germany
Panelists
John Borg, Malta; Marina Zemskova, USA
- MC3/MC4R inhibition for cachexiaDan Marks, USA
- GDF15 inhibition to reduce cachexia and promote anti-tumor therapyEric Roeland, USA
- S-pindololAndrew Coats, Australia
- Presentation title to be announcedSpeaker to be announced
- Discussion
Cachexia in chronic illness: update 2026
Chairs
Kamyar Kalantar-Zadeh, USA; Annemie Schols, Netherlands
- Cachexia in heart failure – still an issueMarija Zdravkovic, Serbia
- Cachexia in Type 2 Diabetes Mellitus – update 2026Mitja Lainscak, Slovenia
- COPDNeil Greening, UK
- Cachexia in MASH / MASLDSrinivasan Dasarathy, USA
- Discussion
Lunch break
The emerging role of ACTAs across muscle wasting disorders
Chairs
Stefan Anker, Germany; Andrew Coats, Australia; Marija Zdravkovic, Serbia
- S-pindolol: preclinical evidence in the context of GLP-1 treatmentHenning Langer, Germany
- The impact of various muscle anabolic on lean / fat mass changes in response to incretinsMitja Lainscak, Slovenia
- S-oxprenolol in ALS: addressing an unmet need in progressive muscle lossAngelico Carta, Italy
- Panel discussion
SCWD symposium supported by Actimed Therapeutics
Pediatric cancer cachexia
Chairs
Erin Talbert, USA; Paola Costelli, Italy
- Biomarkers of the systemic response to cancer in childrenDaniel Runco, USA
- Postnatal neuromuscular growth and the consequences of pediatric cancer therapiesJoe Chakkalakal, USA
- Pediatric CHOP chemotherapy acutely disrupts satellite-cell dynamics and blunts muscle mass in a sex-specific mannerMichael Wiggs, USA
- The surgeon’s viewRichard Skipworth, UK
- Discussion
Defining cachexia, sarcopenia, and frailty
Chairs
Reshma Merchant, Singapore; Gustavo Duque, Canada
- The conceptual and operational definition of sarcopeniaBen Kirk, Australia
- Measuring muscle quantity and quality, the options: DEXA, CT, MRILars Johansson, Sweden
- From sarcopenia to frailty and cachexia: clinical phenotypes, overlap, and outcomesPaul Coen, USA
- Sarcopenic obesity in CKD: a difficult entityAngela Wang, Singapore
- Discussion
Break
Poster viewing 3
Each presentation: 2 minutes + 2 minutes discussion
- Poster session 3.1 · Muscle Wasting & Sarcopenia IV (posters 4-37 to 4-48)Chairs: Ishan Roy; to be announced
- Poster session 3.2 · Nutrition and Appetite + Physical Activity and Training (posters 5-01 to 5-04 and 6-01 to 6-06)Chairs: Morten Hostrup; to be announced
Rapid fire abstracts Session 3
Chairs
Kamal Awad, USA; Laure Bindels, Belgium; Yi-Ping Li, USA
Each presentation: 3 minutes + 2 minutes discussion
- 15:35–15:40 · Plasma metabolites associated with cachexia in chronic obstructive pulmonary disease (1-05)Archana Yadav, USA
- 15:40–15:45 · Human neuromuscular organoid for decoding cancer-induced muscle cachexia (1-08)Pietro Chiolerio, Italy
- 15:45–15:50 · AMPK-endocytosis axis links copper dysregulation to adipose wasting in cancer cachexia (2-07)Honglei Ji, Germany
- 15:50–15:55 · Tumor Cell-Derived CTGF Remodels the Pancreatic Tumor Microenvironment and Mediates Cancer Cachexia via driving TGF-beta production (2-08)Brittney Poole, USA
- 15:55–16:00 · Complement component C5a receptor 1 signaling mediates pancreatic cancer-induced muscle pathologies (2-11)Talya Binienda, USA
- 16:00–16:05 · Olanzapine restores appetite and reduces circulating IL-6 levels in the C-26 model of cancer cachexia (2-14)Rafael Ribeiro Correia, USA
- 16:05–16:10 · Targeting chemotherapy-induced senescence to preserve skeletal muscle function in cancer cachexia (3-02)Sarah A. Ashiqueali, USA
- 16:10–16:15 · Symptom burden reveals distinct clinical and biological phenotypes of cancer cachexia beyond weight loss (3-26)Anlan Cao, USA
- 16:15–16:20 · Dose-limiting treatment toxicity associated to variations of body composition and mortality in patients with metastatic colorectal cancer: numbers at risk in a population-based cohort (4-30)Seil Ko, Canada
- 16:20–16:25 · A Mitochondrial Phenotype of Premature Sarcopenia in Adult Survivors of Childhood Acute Lymphoblastic Leukemia (4-31)Puneet Bagga, USA
Meet-the-editor session
Moderator
Andrew Coats, Australia
Panelists
- Journal of Cachexia, Sarcopenia and MuscleStefan Anker, Germany
- Journal of Gerontology: Biological SciencesGustavo Duque, Canada
- Skeletal MuscleDavid Glass, USA
- Clinical Nutrition section of Frontiers in NutritionMaurizio Muscaritoli, Italy
Frailty, sarcopenia and cachexia in chronic liver disease: from mechanisms to therapies
Chairs
Jose Garcia, USA; Sandra Kleiner, Germany
- Frailty and sarcopenia in patients with cirrhosisNicole Welch, USA
- Mechanisms of muscle dysfunction in MASLDNicolas Lanthier, Belgium
- Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosisJennifer Lai, USA
- GLP-1 agonists for MASLD-associated sarcopenia and muscle dysfunctionGrace Kulik, USA
- Discussion
Cancer Cachexia Endpoints
Chairs
Stefan Anker, Germany; To be announced
- Meaningful quality of life and patient-reported outcome measures – QLQ-C15-PAL, FACIT-Pal, QLQ-C30 Physical Functioning, PROMIS Physical Function, FAACT-A/CS, FAACT-5IASS, and beyondDavid Cella, USA
- Physical function outcomes – HGS, SPPB, 6MWTD etc.Eric Roeland, USA
- Hard outcomes for morbidity & mortalityTim Friede, Germany
- Discussion
Data mining the electronic medical record and imaging for diagnostics in cachexia / sarcopenia
Chairs
Ishan Roy, USA; To be announced
- Automated CT/L3-based body composition pipelines; AI-based opportunistic screening from routine clinical imagingFaisal Beg, Canada
- Defining cachexia staging and phenotypes using data from a large health systemEd Reznik, USA
- Comprehensive full-torso automated assessment of body composition on CTRonald Summers, USA
- Discussion
Industry session · Details to be announced
Connect research with clinical practice.
SCWD 2026 · Washington, DC · December 10–12
DEC12DAY 3
Saturday, 12 December 2026
Young Investigators Award Session (YIA)
Chairs / Judges
James Carson, USA; Paola Costelli, Italy; Mitja Lainscak, Slovenia; Reshma Merchant, Singapore; Hidetaka Wakabayashi, Japan; Teresa Zimmers, USA
- The liver-gut-muscle axis as a therapeutic target for cachexia in head and neck cancer (1-09)Patrick Livingston, USA
- A consensus progression axis reveals ordered metabolic and signaling reprogramming across organs in PDAC cachexia (1-10)Tingbo Guo, USA
- The S100A8/A9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice (2-27)Lin Gao, China
- Circulating and tumour-derived protein signatures of cachexia in pancreatic and periampullary cancer: a 1033-plex analysis of plasma and paired patient-derived tumour organoid secretomes (3-33)Niels Ruber, Netherlands
- Who shows a greater response to exercise? Sedentary time as a modifier of sarcopenia-related functional response in older women (6-03)Jiwon Yang, Republic of Korea
- Mitochondrial oxidative phosphorylation complex expression in the tumor microenvironment of cachectic and weight-stable colorectal cancer patients (3-04)Bruna Sottili, Brazil
Exercise for cancer cachexia ?!
Chairs
Scott Bowen, UK; Marilia Seelaender, Brazil
- Resistance vs. aerobic vs. combined training in cancer cachexiaRichard Dunne, USA
- Pharmacological mimics of exercise: novel strategies to augment muscle mass and functionMorten Hostrup, Denmark
- Pharmacological possibilities to help patients to move moreBo Falck Hansen, Denmark
- Exercise versus anabolic drugs for treating sarcopeniaPhil Atherton, UK
- Discussion
Break
Poster viewing 4
Each presentation: 2 minutes + 2 minutes discussion
- Poster session 4.1 · Cachexia – animal models (posters 2-01 to 2-11)Chairs: Andrew Judge, Xiling Shen
- Poster session 4.2 · Cancer cachexia (posters 3-23 to 3-34)Chairs: Egidio Del Fabbro, Joanna Lima
- Poster session 4.3 · Muscle Wasting & Sarcopenia (posters 4-13 to 4-24)Chairs: Benjamin Miller, Ilse Vanhorebeek
GLP-1RA for weight loss therapy: the issue of muscle and bone loss
Chairs
Stefan Anker, Germany; Andrew Coats, Australia; Bo Falck Hansen, Denmark
- Sex-dependent decreases in organ weight with GLP-1RAKatsu Funai, USA
- Liver, heart and bone during incretin treatmentHenning Langer, Germany
- Myostatin/activin-pathway combination-therapy trial data (e.g., bimagrumab + GLP-1 agonist)David Glass, USA
- The experience with enobosarmMitchell Steiner, USA
- Beyond lean mass preservation: Cardiometabolic effects of anabolic add-on therapies for weight lossKen Attie, USA
- Discussion
From signals to systemic wasting: crosstalk in cancer cachexia
Chairs
Lynda Bonewald, USA; Marcus Goncalves, USA
- Impaired T cell functionality contributes to cancer cachexiaSu-Ping Ng, Germany
- Tumor-secreted ADAMTSL4 activates latent TGF-β1 to drive cancer cachexiaMauricio Berriel Diaz, Germany
- The adipose tissue as an active driver of cancer and cachexia progression: depot-specific features and novel targetsAlessio Molfino, Italy
- The gonad-bone-muscle axis in cancer and treatment-induced cachexiaJames Carson, USA
- Discussion
Late breaking science & trials
Chairs
To be announced; To be announced
- A) Sarcopenia related
- PEP-421, a novel ultra-long-acting CRHR2 agonist, promotes weight loss while preserving skeletal muscle during semaglutide treatment (7-14)Keld Fosgerau, Denmark
- Assessment of lean mass, skeletal muscle volume and strength from a 12-week Phase 1 randomized controlled trial using trevogrumab, a myostatin inhibitor, in healthy older adults (4-21)Jennifer Lighter, USA
- RJx-01 improves recovery of muscle strength and function following immobilization in older adults: integrated clinical and transcriptomic evidence from a Phase 1b trial (7-01)Jeroen Aerssens, Belgium
- MF-300 in age-related sarcopenia: a Phase 2b design evaluating physical function, muscle strength and patient-reported outcomes (7-03)Jose Garcia, USA
- B) Cancer cachexia related
- A Phase 1b dose escalation study of an anti-GDF-15 monoclonal antibody, Rilogrotug (Rilo, AV-380), for cancer cachexia (7-04)Eric Roeland, USA
- REACH (Rilogrotug TrEatment of Anorexia in Cancer CacHexia): a randomized, double-blind study of rilogrotug versus placebo in patients with cancer cachexia and metastatic colorectal cancer (mCRC) or metastatic non-small cell lung cancer (mNSCLC) (3-20)Claudia Lebedinsky, USA
- IMPACT-ONE: design of a randomized, double-blind, placebo-controlled Phase 2b trial of (S)-pindolol benzoate on body weight and functional outcomes in patients with cachexia due to non-small cell lung cancer (7-02)Uwe Pelzer, Germany
- Efficacy and safety of ponsegromab in non-small cell lung cancer and cachexia: a subgroup analysis of PROACC-1 phase 2 study (3-24)Jeffrey Crawford, USA
- Discussion
Neural inflammatory and behavioral axes in cachexia
Chairs
Laure Bindels, Belgium; Alessio Molfino, Italy
- Mechanisms of behavioral changes in cachexiaTobias Janowitz, USA
- Targeting the peripheral and systemic gut-brain axes to combat cachexiaXiling Shen, USA
- Metabolism and behavior in cancer cachexiaEileen White, USA
- Sympathetic nerve mediated factors in cachexiaAaron Grossberg, USA
- Discussion
Industry session · Lunch
Ken Fearon Career Café · Meet the Mentor (attendance upon application and confirmation)
Emerging treatments in neuromuscular disease
Chairs
David Glass, USA; Fabio Dorigotti, Switzerland
- Fibroadipogenic progenitors as a therapeutic target in dystrophic muscleMarshall Hogarth, USA
- (s)-oxprenolol for ALSJochen Springer, Germany
- Anti-inflammatory strategies in neuromuscular diseaseAgata Mossakowski, Germany
- Genetic modifiers in neuromuscular diseasesAlexis Demonbreun, USA
- Discussion
Bone–muscle crosstalk in cachexia and sarcopenia
Chairs
Kamal Awad, USA; Gustavo Duque, Canada
- General bone–muscle crosstalk: mechanisms and implicationsLynda Bonewald, USA
- Liver-bone-muscle-cancer interactions: clinical perspectives and therapeutic opportunitiesAndrea Bonetto, USA
- Osteocyte mediated bone-muscle crosstalk in cancer cachexiaFabrizio Pin, USA
- Integrative musculoskeletal biomarkers: myokines, osteokines, and beyond in sarcopenia and osteoporosisMarco Brotto, USA
- Discussion
Highlights session · Hall A · Chairs: Teresa Zimmers, USA; Maurizio Muscaritoli, Italy. Basic science: Aaron Grossberg, USA. Sarcopenia: to be announced. Cancer cachexia: Brittany Counts, USA. Poster Award · Young Investigator Award · Farewell.
Be part of the scientific exchange.
SCWD 2026 · Washington, DC · December 10–12
The questions moving
the field forward.
Five scientific threads connecting mechanisms, measurement and care across the 2026 programme.
Weight loss.
What about muscle?
Explore muscle and bone loss during GLP-1 treatment, multi-organ effects and combination therapies designed to preserve muscle.
David Glass · Katsu Funai · Andrew Coats
Explore Saturday's sessionsNew targets.
New clinical questions.
GDF15 inhibition, MC3/MC4R inhibition, s-pindolol and the endpoints that matter in cancer cachexia trials.
Eric Roeland · Dan Marks · Stefan Anker
Explore Friday's sessionsSee more in
clinical data.
AI-assisted screening from routine imaging, automated body-composition analysis, electronic medical records and wearable technology.
Faisal Beg · Ed Reznik
Explore Friday's sessionsFrom discovery to clinical practice
Opening keynotes by Denis Guttridge and Jeffrey Crawford, plus COACH-ED discussions on diagnosing and treating cancer cachexia.
Exercise, nutrition & muscle function
Research on exercise, protein intake and functional outcomes, connecting biological mechanisms with clinical questions.
Bring your questions to Washington.
Meet the people investigating them.
Meet the science.
Meet the people.
Featured contributors listed in the 2026 scientific programme.

Teresa Zimmers
OHSU Knight Cancer Institute, Oregon Health & Science University
Responder analysis in the PACTO trial
Kamyar Kalantar-Zadeh
UCLA David Geffen School of Medicine · Harbor-UCLA Medical Center
Cachexia in CKD and AKI
Eric Roeland
OHSU Knight Cancer Institute, Oregon Health & Science University
GDF15 inhibition to reduce cachexia and promote anti-tumor therapy
Marilia Seelaender
University of São Paulo · Faculty of Medicine
Cachexia as multi-organ disease
Find your next conversation.
Posters, rapid-fire abstracts, the Career Café and the welcome reception bring people together beyond the sessions.
Sponsors of SCWD 2026
Thank you to the organisations supporting SCWD 2026. Further sponsors will be added as they are confirmed.
SCWD 2026.
Be there in person.
December 10–12 · Washington, DC
Join clinicians and researchers for three days dedicated to cachexia, sarcopenia and wasting disorders.
Registration and ticket options are available on the official SCWD website.


































































